6242392
Last Update Posted: 2024-02-05
Recruiting has not begun
Females accepted | 18 Years + |
250 Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment. The efficacy was evaluated according to RECIST criteria, comparing the correlation between different HRD statuses and the efficacy of PARP inhibitors in ovarian cancer.
Eligibility
Relevant conditions:
Ovarian Neoplasms
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov